The EDV nanocell is a first-in-class cyto-immunotherapy platform targeting the tumor directly and leveraging the patient’s own immune system.




  • Works against mutant strains including Delta

  • No need for refrigeration during transport and storage

  • No added stabilisers or chemicals

  • Safety and immune response clinical trial recruiting now in Melbourne

  • Efficacy trial planned for USA.

For more information about becoming a volunteer for the COVID-19 EDV™ Vaccine Trial contact:

Despina Anagnostou - St Vincents Hospital Melbourne

+61 3 9231 3490         Despina.Anagnostou@svha.org.au


Learn more about EnGeneIC Dream Vector (EDV™) Nanocell platform technology

Publication in prestigious scientific journal, Cancer Cell, highlighting the ability of EDV™ Nanocells to mount dual assault on Cancer Cells

EDV™ Technology Stimulates Both Innate and Adaptive Immune Response and Confers Long-Term Survival

Abstract accepted  to the Annual Meeting of the American Society of Clinical Oncology 2020

Abstract Demonstrates Promising Early Results from Phase I/IIa study in Patients with Recurrent, Metastatic Pancreatic Cancer.